Leukopenia, anemia and thrombopenia occur frequently.
Nausea and vomiting are the most commonly reported side effects.
Other adverse reactions are:
Pancytopenia; eosinophilia; hemolytic anemia; bleeding
tendencies such as petechiae, purpura, epistaxis and hemoptysis.
Hepatic dysfunction, jaundice, stomatitis, hematemesis,
melena, diarrhea, dysphagia, anorexia, abdominal pain, constipation, dry mouth.
Coma, convulsions, neuropathy, ataxia, paresthesia,
nystagmus, diminished reflexes, falling, foot drop, headache, dizziness,
Hypotension, tachycardia, syncope.
Retinal hemorrhage, papilledema, photophobia, diplopia,
inability to focus.
Pneumonitis, pleural effusion, cough.
Herpes, dermatitis, pruritus, alopecia,
hyperpigmentation, rash, urticaria, flushing.
Generalized allergic reactions.
Hematuria, urinary frequency, nocturia.
Pain, including myalgia and arthralgia; tremors.
Hallucinations, depression, apprehension, nervousness,
Gynecomastia in prepubertal and early pubertal boys.
Intercurrent infections, hearing loss, pyrexia,
diaphoresis, lethargy, weakness, fatigue, edema, chills, insomnia, slurred
speech, hoarseness, drowsiness.
Second nonlymphoid malignancies (including lung cancer,
acute myelocytic leukemia and malignant myelosclerosis) and azoospermia have
been reported in patients with Hodgkin's disease treated with procarbazine in
combination with other chemotherapy and/or radiation. The risks of secondary
lung cancer from treatment appear to be multiplied by tobacco use.
See WARNINGS section.
No cross-resistance with other chemotherapeutic agents,
radiotherapy or steroids has been demonstrated.